OBJECTIVES: This study evaluated the safety, efficacy and clinical performance of the tissue-engineered ADAPT® bovine pericardial patch (ABPP) in paediatric patients with a range of congenital cardiac anomalies.
INTRODUCTION
A wide range of synthetic [1] , biological [1, 2] and autologous [3, 4] materials have been used to correct congenital cardiac defects in newborns and paediatric patients (Table 1) . Extracellular matrix biomaterials of xenogeneic origin, such as bovine pericardium, have been used extensively in the cardiovascular area since 1977 when Ionescu et al. [5] constructed prosthetic heart valves from glutaraldehyde-preserved bovine pericardium. Bovine pericardium has been successfully used for closure of atrioseptal defects (ASDs), ventricular septal defects (VSDs) and reconstruction of the right ventricular outflow tract (RVOT) [6] .
It is well known, however, that glutaraldehyde-preserved bovine pericardium is subject to degenerative processes involving rigidity, calcium deposition and structural changes (shrinkage) after implantation in humans with the subsequent failure of the bioprosthesis, mainly due to the toxicity of glutaraldehyde residues [7] and host immune responses [8] . Although the complication rate with ASD and VSD closure is low, complications such as thrombus formation on synthetics [9] , formation of aneurysms in biologics [10] and dehiscence of calcified patches have been documented [11] .
The present study was, therefore, conducted to evaluate the efficacy, safety, thrombogenicity, handling characteristics, haemostatic status and calcification potential of a tissue-engineered bovine pericardial patch-offering a significant level of biocompatibility and durability-in a variety of congenital cardiac repair procedures.
MATERIALS AND METHODS

Study design
This was a single-centre, prospective, non-randomized clinical study to assess the tissue-engineered ADAPT® bovine pericardial patch (ABPP; CardioCel®, Celxcel Pty Ltd., Perth, Western Australia) in paediatric patients diagnosed with a range of congenital cardiovascular anomalies. The research protocol was reviewed and approved by the Clinical Ethics Committee of the Medical School of the Free State University, Bloemfontein, South Africa, and informed consent was obtained prior to surgery.
Patients were evaluated preoperatively to obtain baseline values of haematology parameters and to perform a general cardiology assessment. Each patient's functional status was categorized according to the standardized New York Heart Association (NYHA) classification system. Intraoperatively, surgical assessment included handling characteristics, haemostasis and overall seating of the implanted patch. Characteristics were assessed according to a Likert-type scale with measures from 0 to 10 (where 0 = poor and 10 = excellent).
Postoperative evaluation was performed at 6 and 12 months and consisted of echocardiographic evaluation using standard 2D-M mode echocardiography examination (HP3000, Hewlett Packard, JHB, South Africa) to determine device-related changes, haematocompatibility and calcification. Echocardiographic parameters included device rocking, device thickening, thrombus formation, calcification and the presence of vegetations or pseudoaneurysms. Magnetic resonance imaging (MRI; Philips 2000 ACT, Phillips, JHB, South Africa) was performed on 10 randomly selected patients at 12 months to determine micro-calcification levels of the implanted patch. Selection for MRI assessment was based on a representative distribution of the different spectrum of procedures (VSD = 5 patients, complex procedures = 4 and vascular procedures = 1). Patients completing the 12-month study were eligible to enter a long-term evaluation study.
Efficacy measures
Primary efficacy measures included early (<30 day) morbidity (defined as graft failure, thromboembolic events, structural leak, infections, device-related re-operations or device replacement); the incidence of device-related complications and haemodynamic performance derived from echocardiography assessment (calcification, surface thickening and the presence of thrombi). Secondary objectives included device-handling characteristics, shape and sizing characteristics and perioperative implant complications.
Patients
Patients were eligible for inclusion if they had symptoms and anatomy sufficient to warrant application of the ABPP as a bioprosthetic substitute during surgical repair procedures during open-heart surgery. Specifically, this involved ASD, VSD, atrioventricular septal defect (AVSD), aortic root enlargement and RVOT reconstruction. Patients undergoing concomitant procedures such as coronary artery bypass or valve replacement were also eligible for inclusion. A detailed list of complete procedures and concurrent Aristotle risk assessment is provided in Table 2 .
Tissue-engineered pericardial patch
The tissue-engineered ABPP is manufactured from bovine spongiform encephalopathy-free pericardium. Manufacturing consists of several tissue engineering processes, which include steps to remove lipids, cells and cell remnants, nucleic acids (DNA, RNA) and Gal epitopes. In addition, cross-linking is achieved with an ultra-low engineered glutaraldehyde concentration to minimize glutaraldehyde cytotoxicity levels (Allied Healthcare Group Ltd. proprietary). Cytotoxicity is further reduced to zero levels by the ADAPT® anti-calcification process and a non-glutaraldehyde sterilization and storage solution with added anti-calcification properties [12] .
Operative procedures
A range of surgical procedures were performed in patients with a variety of congenital cardiac lesions. In all patients who underwent open-heart operations, a medial sternotomy was performed. The pericardium was opened. Heparin was given at 3 mg/kg and the patient cannulated. A bicaval venous cannulation strategy was followed in virtually all instances. The bypass was run at a circulating temperature of 30°C, except when patients were cooled for circulatory arrest or low-flow by pass strategies.
A four-to-one blood-to-cardioplegia Buckberg solution was used throughout the series.
After completion of procedures, the patients were weaned from cardiopulmonary bypass, drains were inserted and, after heparin reversal with protamine and attention to haemostasis, the chests were closed with usually at least one temporary pacemaker wire attached to the right ventricle. 
Mortalities
Two patients died within the first 30 postoperative days (early mortality): One patient who was diagnosed with a hypoplastic aortic arch, coarctation and transposition of the great arteries died 3 days postoperatively due to acute respiratory distress syndrome due to transfusion-related lung injury. A second patient died as a result of pulmonary hypertensive crisis after correction of a truncus arteriosus. Three patients died >3 months postoperatively (late mortality): 1 patient (aged 3 months) died of a bilateral chylothorax and septicaemia. A second patient (aged 18 months) contracted community-acquired pneumonia and died of sepsis and low pulmonary perfusion. A third patient (aged 5 years) died 3 months postoperatively in a community hospital of cardiac arrest.
Statistical analysis
Statistics were performed using SigmaPlot (Systat Software, Inc., San Jose, CA, USA) Version 11.0 (Exact Graphs and Data Analysis) for windows and R version 3.0.0 (The R Foundation for Statistical Computing, 2013).
Patient demographic and baseline characteristics were summarized as frequencies and percentages for categorical variables and values were expressed as mean ± standard deviation (SD) or median (range). Differences in survival for low (Aristotle complexity score ≤8) and high (Aristotle complexity score >8) complexity surgical repairs were tested using Fisher's exact test.
RESULTS
From April 2008 to September 2009, tissue-engineered ADAPT-treated bovine pericardium was used in the repair of congenital heart defects in 30 non-consecutive patients at the University Hospital, Medical School, University of Free State in Bloemfontein, South Africa. Seventeen (57%) patients were male. Twenty (67%) patients had a NYHA classification I at baseline. Fourteen (47%) had a VSD only, with the remaining patients having a variety of congenital heart defects. None of the patients had any concomitant procedures. Patient demographics and baseline characteristics are presented in Table 3 .
In the 30-day postoperative period, no graft-related morbidity (i.e. graft failure, thromboembolic events, structural leak, infections, device-related reoperations or device replacement) was observed. In total, there were 5 deaths, all determined as non-graft-related. Two deaths occurred early (in the 30-day postoperative period) and the remaining 3 occurred late (up to 6 months postoperatively). Two (6.7%) patients were lost to followup. Geographical, relocation and travelling difficulties were cited as reasons for the lack of follow-up, a known difficulty for clinical trials in South Africa.
Echocardiography was performed in 22 patients at 6 months and 19 at 12 months (Table 4) . A residual leak was identified in 1 patient. However, the technician considered the finding to be non-graft-related. MRI assessments in 10 patients at 12 months revealed no detectable micro-calcification levels.
Perioperative assessment of handling characteristics is presented in Table 5 . In general, the graft characteristics were rated as 'excellent'. The 'elasticity' of the graft was rated as less than satisfactory in 7 (23%) implants. In all cases, the shape and sizing characteristics for each implant scored highly (Table 6 ). In 1 case, involving a 3-month-old infant, the surgeon would have preferred a thinner graft. 
ORIGINAL ARTICLE
The complexity of the surgical repair was scored using the Aristotle complexity score. The 5 patients who died had a significantly higher score than those who survived [mean = 12.40 (1.70) for deceased patients, 7.02 (2.41) for surviving patients; P-value <0.0001 from t-test]. Fisher's test indicated that those with highcomplexity surgical repairs had significantly lower survival rates than those with low-complexity repairs (P-value = 0.0055; 58% survival in the high-complexity group and 100% survival in the low-complexity group).
No further deaths were reported throughout the 12-month or extension phase of the study. Nineteen patients entered the longterm evaluation study. A total of 19 patients have been evaluated at 18 months, 12 at 24 months, 13 at 36 months and 7 have reached 48 months of follow-up. In all cases, there was no echocardiographic evidence of device calcification, infection, thromboembolic events or device failure. Haemodynamics were intact.
DISCUSSION
In this single-centre, non-randomized, prospective study, we have demonstrated medium-term durability, efficacy and favourable haemodynamic properties of the ABPP when used to repair a variety of congenital heart defects in paediatric patients followed for 6-48 months. In addition, the device offers appropriate handling characteristics, including thickness, flexibility and elasticity. In the medium term, we have demonstrated that the ABPP has favourable anticytotoxic properties exhibiting no evidence of implant cytotoxicity or calcification at 48 months of follow-up.
To date, there have been a number of case reports and retrospective studies performed demonstrating the utility of bovine pericardial patches (BPPs) in the use of congenital heart repair [1, 5, 6, 13] . However, very few prospective studies have been performed and indeed, no prospective studies undertaken to evaluate BPP specifically for the repair of ASD, VSD, AVSD and RVOT.
A variety of synthetics and bioprosthetic materials (homografts, xenografts and porcine intestinal sub-mucosa) have been used for cardiovascular applications, including the repair of congenital heart deformities. However, calcification and degeneration remain limiting factors in terms of their longevity and clinical effectiveness [13] , as do the inability to grow with the patient's heart, loss of mechanical strength over time and little ability to remodel or regenerate. These materials are also associated with the risk of infection and aneurysm, in addition to the cytotoxic effects of various cross-linking agents [14] .
Advances in paediatric cardiology and cardiac surgery have resulted in a change in the prevalence and age distribution of patients with congenital heart disease (CHD) [15, 16] . Because of a decline in overall mortality among children born with CHD, more patients are reaching adulthood, including those with severe disease, who previously did not survive [15] . Thus, when selecting patch material, consideration should be given to the implications of the changing demographics and longer life expectancy of patients undergoing repair of congenital heart defects.
Future patch material used for the repair of CHD should be biocompatible, i.e.biodegradable, bio-reabsorbable and mechanically strong, and have the ability to be formed into different shapes as required. In addition, the ability to grow with the patient is critical in the light of the changing demographics of CHD [14] .
It is evident from the literature that the ideal prosthetic material for the repair of congenital heart deformities remains elusive. However, the ABPP represents a significant advance. The absence of graft-related morbidity and any observable calcification (on Table 5 : Surgeon-reported assessment of handling characteristics Handling quality, n (%)
Graft used for the 3-month-old infant-surgeon would have preferred a thinner graft for that specific case. both echocardiography and MRI assessment) are promising signs. Furthermore, follow-up data collected beyond 12 months (range 14-36 months between ABPP and alternative xenograft materials) support the durability of the ABPP. Although direct comparisons should be treated with caution, our follow-up period is relatively close to the reported follow-up with other currently available xenografts yet we are still to observe intimal peel formation or stenosis, as seen in studies of those materials [17, 18] . Ongoing follow-up will continue in our cohort of patients to assess longterm durability of the ABPP. This study was a non-randomized, single-centre experience with relatively small patient numbers, and the results should be interpreted in the light of this limitation. The device was tested without a control group and follow-up was incomplete over 12 months. There is the possibility that incomplete follow-up may add selection bias, which could have influenced the total outcome in graft calcification during that period. With regard to the characteristics of the ABPP, we also acknowledge that handling characteristics and surgeonrelated quality are subjective measures and susceptible to operator bias. Nevertheless, in this initial experience, the ABPP consistently demonstrated appropriate characteristics, including thickness, flexibility and elasticity. The ADAPT®-treated bovine pericardium (CardioCel®) is currently under consideration for regulatory approval in a number of global markets. CardioCel is currently being used in Australia as part of a Therapeutic Goods Administration (TGA) authorized prescriber scheme for repair of congenital heart defects. The patch is not currently available in other regions. CardioCel® is expected to be launched by the Allied Healthcare Group Ltd. in the global market pending regulatory approval.
In summary, we have shown that in paediatric patients with a range of congenital heart deformations, followed for 12-36 months, the ABPP demonstrated durability, efficacy and favourable haemodynamic properties. No clinically significant calcification was observed, and there was no graft-related morbidity or mortality. The ABPP may provide a solution to the current need for durable, safe and effective implants within the context of the changing demographics of CHD.
